These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17461210)

  • 21. [Cerebral infarction--thrombolytic therapy by tissue-type plasminogen activator or prourokinase].
    Amano T
    Nihon Rinsho; 1989 Apr; 47(4):917-20. PubMed ID: 2501542
    [No Abstract]   [Full Text] [Related]  

  • 22. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
    Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
    Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brainstem infarction secondary to persistent trigeminal artery occlusion: successful treatment with intravenous rt-PA.
    Kwon JY; Lee EJ; Kim JS
    Eur Neurol; 2010; 64(5):311. PubMed ID: 21051896
    [No Abstract]   [Full Text] [Related]  

  • 25. The tissue-type plasminogen activator story.
    Collen D; Lijnen HR
    Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1151-5. PubMed ID: 19605778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolysis for Acute Ischemic Stroke After Protamine Reversal of Heparin.
    Danoun O; Sachar P; Rajamani K
    Am J Ther; 2018; 25(5):e552-e554. PubMed ID: 29199997
    [No Abstract]   [Full Text] [Related]  

  • 27. Potential for treatment with thrombolysis in an Irish stroke unit.
    Collins DR; O'Neill D; McCormack PM
    Ir Med J; 1999; 92(1):236-8. PubMed ID: 10360096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. rt-PA with Antithrombotic Therapies in a Case with Capsular Warning Syndrome.
    Fuseya Y; Kawamura M; Matsuda E; Takada K; Watanabe K; Fujitake J; Nakaya Y
    Intern Med; 2017; 56(4):441-444. PubMed ID: 28202868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction.
    Van de Werf FJ; Topol EJ; Sobel BE
    J Thromb Haemost; 2009 Jan; 7(1):14-20. PubMed ID: 19090814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safe use of thrombolysis in the elderly.
    Wittry MD; Thornton TA; Chaitman BR
    Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
    Cocho D; Belvís R; Martí-Fàbregas J; Molina-Porcel L; Díaz-Manera J; Aleu A; Pagonabarraga J; García-Bargo D; Mauri A; Martí-Vilalta JL
    Neurology; 2005 Feb; 64(4):719-20. PubMed ID: 15728300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tissue-type plasminogen activator].
    Turazza FM; Pogna M
    Medicina (Firenze); 1990; 10(1):75-8. PubMed ID: 2116566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA.
    Fernandez-Cadenas I; Mendioroz M; Munuera J; Alvarez-Sabin J; Rovira A; Quiroga A; Corbeto N; Rubiera M; Delgado P; Rosell A; Ribó M; Molina CA; Montaner J
    Thromb Haemost; 2009 Oct; 102(4):759-64. PubMed ID: 19806263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Right atrial thrombus treated with T-PA.
    Proença G; Caetano F; Cardoso P; Segurado F; Forjaz A
    Rev Port Cardiol; 2000 Mar; 19(3):367-9. PubMed ID: 10804783
    [No Abstract]   [Full Text] [Related]  

  • 39. Tissue-plasminogen activator: a new drug in reperfusion therapy (continuing education credit).
    Strauss E; Rudy EB
    Crit Care Nurse; 1986; 6(3):30-5, 38-43. PubMed ID: 3089687
    [No Abstract]   [Full Text] [Related]  

  • 40. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.